Our mission
Transmural Biotech develops innovative products and services in the clinical field through image analysis technologies that allow personalized, economical, non-invasive and efficient medicine.
LEADERS – We are one of the 20 most important MedTech companies in the world.
VANGUARD – We develop medical technologies based on image diagnosis through artificial intelligence. Two basic platforms: image-based AI and algorithms as a predictive basis for medical diagnosis.
COMMITTED TO MEDICINE– We are committed to a personalized, predictive, non-invasive, rapid and reliable clinical diagnosis..
INTERNATIONAL SOUL – We are committed to a global distribution.
Products
COUNTRIES
can benefit from our technology
CLINICS AND HOSPITALS
around the world provide our tests
DIAGNOSTIC TEST
successfully performed since 2016
POSITIVE EXPERIENCES
of patients who have trusted us
Last News
The advances in medical technologies of Transmural Biotech have earned a place in the media. Our belief to the medicine of the future and our commitment to science are news.
ASISA visit to the Unimed Faculty
Last week, David Fernandez, Director of Transmural Biotech and representative of the Spanish medical cooperative ASISA, visited the headquarters of the Faculty of Unimed. During the visit, David Fernandez visited the facilities and participated in a meeting with the President of the Unimed Foundation and CEO of the Unimed Faculty, Helton Freitas, Academic Director Fabio Leite Gastal, Business and Operations Manager Vinícius Borges, Educational Solutions Development Coordinator Aline Mattos and Distance Education Technology Coordinator Renata Carolina Figueira Serpa, to discuss the educational projects to be developed in partnership between the institutions.
Transmural Biotech, in the Top 10 of companies proposing AI-based healthcare solutions with the greatest impact on the sector
The rapid pace of technological, medical and scientific innovation is transforming the narrative in the biopharma indutry. With the incresing need for better patient engagement and expirience…
Miguel Ángel Lorente, CEO of Transmural Biotech, analyzes the performance of the sector in the digital magazine Capital
Spanish biotechnology continues to grow and achieve international recognition. In the context of the pandemic, Capital analyzes the behavior of the sector with Miguel Ángel Lorente, CEO of Transmural Biotech.
Transmural Biotech receives the award for ‘most promising innovation in digital medicine’ for ‘QuantusFLM’
The biotechnology company Transmural Biotech has received the award for “most promising innovation in digital medicine” at the third edition of the Digital Medicine Conference (DMC) held in New York, for the development of ‘QuantusFLM’.
We are one of the most relevant digital companies, according to ‘The Silicon Review’
The annual ranking of one of the most prestigious magazines in the world in the biotech sector, “The Silicon Review”, included Transmural Biotech amongst the 50 top companies of 2019. This award celebrates the value and excellence of our work as well as our contribution to the technological and business market.
In the top 20 most innovative medtech companies according to “Technology Innovators”
Transmural Biotech is amongst the most innovative medical technology companies of 2019, according to the magazine “Technology Innovators”. Our focus on a personalized, preventive and non-invasive medicine through the use of state-of-the-art Artificial Intelligence techniques has been internationally recognized.
Award to the most promising innovation in Digital Medicine in 2019 for quantusFLM
We received from the American organization NODE.Health the “Most Promising Digital Medicine Innovation” award for the development of our first product, quantusFLM, during the Digital Medicine Conference 2019, in New York. They judged the test as a technological promise due to the clinical evidence and results validating it.
They trust us
“One of the major challenges in the modern obstetrics has been to determine the Fetal Lung Maturity. But traditional methods based on amniocentesis have the limitation for being invasive and having the risk to cause premature rupture of membranes and preterm labor. quantusFLM is the solution to this clinical dilemma.”
“It is so amazing that we don’t need to analyze the amniotic fluid to determine the fetal lung maturity.”
“Personalized, predictive and non-invasive medicine is the future”
“quantusFLM lets us to know fetal lung maturity based on respiratory morbidity risk with a high reliability, that helps to end labor in the correct moment.”
Our partners
Our research and development work in medical technologies would not be possible without the collaboration of some of the main hospitals, health centers and specialized research groups in Spain and Latin America. Thanks for your support!
Main partner
In collaboration with
Our partner
Our research and development work in medical technologies would not be possible without the collaboration of some of the main hospitals, health centers and specialized research groups in Spain and Latin America. Thanks for your support!
Main partner
In collaboration with